Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORECARD phase II feasibility trial of sildenafil during CABG
ACTRN12616001133426Phase 2Withdrawn
- Sponsor
- The University of Auckland
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing Sildenafil with Placebo (2 arms). Primary endpoints: Pulsatility index, Graft flow and 1 more. Planned start Feb 2017; status: withdrawn.
02
Drugs
sildenafil
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12616001133426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001133426.